• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Leading Cancer Centers Commence Clinical Study for Prostate Cancer Patients Receiving External Beam Radiation Therapy

Posted on: Wednesday, 20 July 2005, 18:01 CDT

SEATTLE, July 20 /PRNewswire/ -- Calypso(R) Medical Technologies, Inc. today announced that it has begun clinical studies for patients with prostate cancer receiving external beam radiation therapy. The study will evaluate the usability and safety of an investigational patient positioning system as an accessory in radiation therapy delivery (Calypso 4D Localization System with permanently implanted Beacon(R) transponders). The Calypso System is designed to provide objective, accurate and continuous tumor location information for external beam radiation therapy without additional ionizing radiation.

The study will take place at clinical facilities that were selected based on their extensive experience in radiation therapy for prostate cancer and desire to bring new technology to their patients. The study evaluates permanently implanted transponders in the prostate that communicate with the Calypso System to guide positioning of the patient for daily radiation treatment. The study will also evaluate the positioning system to continuously track the position of the prostate.

"We expect this investigational platform to provide information on organ motion so that clinicians can better manage treatment during external beam radiation therapy," said Eric Meier, president and CEO, Calypso Medical. "For the first time, it will be possible for clinicians to track the treatment target location continuously throughout treatment. In the future, with increased confidence of knowing where the target is at all times, the clinician may explore expanded treatment delivery options."

Current sites participating in the clinical study include M. D. Anderson Cancer Center Orlando, The Nebraska Medical Center, Scottsdale Healthcare, Cleveland Clinic, and Huntsman Cancer Institute.

In 2005, over 232,000 men will be diagnosed with prostate cancer, more than half of whom will receive radiation therapy to treat the disease.

About Calypso(R) Medical Technologies, Inc.

Calypso(R) Medical Technologies, Inc., was founded in 1999 and is a privately held medical device company located in Seattle, Washington. The Company and its employees are dedicated to enabling clinicians to manage organ motion with solutions designed to improve delivery of radiation therapy. Calypso Medical is a pioneer in solutions designed to accurately, objectively and continuously locate and align targets from inside the body without the addition of ionizing radiation. It has developed an AC electromagnetic localization platform that is currently under clinical study at leading cancer centers. Additional information can be found at http://www.calypsomedical.com/.

Calypso Medical Technologies, Inc.

CONTACT: Virginia Ginsburg of Swell Strategies, +1-310-453-7008,vginsburg@swellstrategies.com, for Calypso Medical Technologies, Inc.

Web site: http://www.calypsomedical.com/

Source: PRNewswire

More News in this Category